AUS
NZ
UK
CA
USA
IND
Healt
Telix Pharma Expands Imaging Focus Across Cancer Care
May 15, 2026 02:46 PM AEST| By SamTelix Pharmaceuticals expands its cancer imaging portfolio with kidney and brain diagnostic advancements, strengthening its healthcare market presence and drawing attention across the biotechnology sector.
Why Anteris Technologies Is Drawing Attention Despite Cash Burn
May 15, 2026 11:03 AM AEST| By SamAnteris Technologies remained in focus as investors weighed its cash runway, cardiovascular innovation strategy, and long-term positioning within the evolving global medtech sector.
ASX 200 Biotech Sector Watch Amid Healthcare Market Activity
May 15, 2026 10:33 AM AEST| By SamAustralian biotechnology stocks remained under market attention as healthcare innovation, medical research participation, and clinical development activity continued shaping broader healthcare sector operations.
Why ASX Functional Beverage Stocks Are Gaining Momentum
May 15, 2026 10:24 AM AEST| By SamASX-listed beverage companies are capitalising on rising demand for wellness drinks, hydration products, protein beverages, and alcohol alternatives as health-conscious consumer behaviour reshapes the global drinks industry.
Osteopore Malaysia Approval Gains ASX 300 Focus
May 15, 2026 09:57 AM AEST| By SamOsteopore strengthened healthcare technology visibility following orthopaedic approval developments linked to regional healthcare expansion activity in Malaysia.
Why This ASX Biotech Name Is Drawing Fresh Market Attention
May 15, 2026 09:35 AM AEST| By SamImugene attracted renewed market attention as investors focused on oncology innovation, advanced cell therapy development, and the broader transformation underway across global healthcare and precision medicine infrastructure.
Tax-Free Edge Driving Attention Towards Acrux Shares
May 14, 2026 05:54 PM AEST| By SamAcrux shareholders remain shielded from Australia’s latest capital gains tax overhaul, strengthening attention on tax-efficient investment structures and the evolving landscape of Australian equities.
Breathes New Life Into Anxiety Care With Clinical Progress
May 14, 2026 03:50 PM AEST| By SamNexalis Therapeutics advances inhaled CBD research after completing an important clinical study milestone, highlighting innovation in mental health treatment and biotechnology development.
Why CSL’s Recovery Story Is Turning Heads on the ASX Stocks
May 14, 2026 03:23 PM AEST| By SamCSL is showing signs of operational recovery as plasma collections improve, vaccine demand remains resilient, and healthcare trends continue supporting long-term growth across specialised global markets.
ASX 200 Healthcare Stock Watch: TLX In Focus
May 14, 2026 12:53 PM AEST| By SamASX biotechnology and healthcare sector remained in focus as TLX continued attracting attention through radiopharmaceutical activity and healthcare innovation developments.
ASX 20 Healthcare Sector Update: CSL Shares And Market Activity
May 14, 2026 10:59 AM AEST| By SamAustralia’s healthcare sector remained active as CSL continued drawing attention through biotechnology operations, plasma services, and pharmaceutical market participation.
Why These ASX Healthcare Shares Are Riding Australia’s Ageing Boom
May 14, 2026 10:31 AM AEST| By SamAustralia’s ageing population continued driving attention toward healthcare and aged care companies as demand for residential care, rehabilitation and hospital services strengthened across the sector.
Why This ASX Biotech Share Is Suddenly Back on the Radar
May 14, 2026 10:08 AM AEST| By SamEBR Systems returned to market focus after commercial growth, expanding hospital contracts and manufacturing developments strengthened attention on the emerging healthcare technology company despite ongoing funding concerns.
Breakthrough ALS Study Pushes Neurizon Into Spotlight
May 13, 2026 07:36 PM AEST| By SamNeurizon Therapeutics advances its ALS research program with ethics approval for an oral liquid study, supporting treatment accessibility and strengthening its broader clinical development strategy.
Healthcare Jitters Deepen After Healius and CSL Shock
May 13, 2026 05:29 PM AEST| By SamHealthcare stocks on the ASX remain under pressure as Healius and CSL trigger renewed concerns around margins, labour costs, funding support and sector-wide earnings stability.
Anteris Expands US Trial Push Amid Heart Valve Focus
May 13, 2026 04:31 PM AEST| By SamAnteris Technologies Global advances its US heart valve trial strategy with fresh funding, manufacturing expansion, and regulatory momentum as clinical development activities continue to strengthen.
ASX Healthcare Stock Expands Capital Base With New Shares
May 13, 2026 11:23 AM AEST| By SamActinogen Medical expanded its quoted share base after issuing additional ordinary shares through option and convertible security exercises.
Amplia Therapeutics Expands Market Presence on ASX Stocks
May 12, 2026 05:30 PM AEST| By SamAmplia Therapeutics expanded its ASX-listed share base, reinforcing biotechnology sector momentum and highlighting continued healthcare innovation activity across Australia’s evolving equity market landscape.
Bioxyne Broadens European Presence Through German Supply Pact
May 12, 2026 02:51 PM AEST| By SamBioxyne broadens its European medicinal cannabis footprint through a major German supply agreement, supporting long-term expansion, stronger revenue visibility, and growing international market access.
CSL Shock Sends ASX Healthcare Sector Into Sharp Retreat
May 12, 2026 01:40 PM AEST| By SamCSL’s sharp decline weighed heavily on the healthcare sector while rising commodity prices supported mining and energy stocks across the australian stock market.
Advertise your brand on Kalkine Media